Guest guest Posted February 15, 2011 Report Share Posted February 15, 2011 For what it's worth............. --- On Mon, 2/14/11, Dannenberg <jdannenberg@...> wrote: From: Dannenberg <jdannenberg@...> Subject: RE: Chronic Myeloid Leukemia Study- will receive $50 " -owner " <-owner > Date: Monday, February 14, 2011, 5:24 PM Dear , Just wanted to send you a quick update about the Chronic Myeloid Leukemia study as described in my previous email below. The participant will now receive $50 in appreciation of his/her valuable input. The study will be running from February 14th through the 28th. Again, if you have any questions or may be interested, please call Elaine at 1-800-683-1287 ext. 127. Kind regards, From: Dannenberg Sent: Wednesday, February 09, 2011 4:47 PM '-owner ' Subject: Chronic Myeloid Leukemia Study Dear , We are conducting a market research study with people who have Chronic Myeloid Leukemia. The study will take about 20 minutes and can be completed online or with one of our interviewers. We would greatly appreciate it if you could pass along this information to anyone that may be interested. He/she will receive $40 in appreciation of their valuable input and contribution to the healthcare industry. The study is being conducted from February 9th to the 28th. If you have any questions or may be interested, please contact Elaine at 1-800-683-1287 ext. 127. Thank you for your time. Kind Regards, Dannenberg Administrative and Project Support Staff Member Performance Plus / Boston Field and Focus 111 Speen Street, Suite 105 Framingham, MA 01701 Office: 508-872-1287 x126 Fax: 508-879-7108 jdannenberg@... Proud Member of GroupNet Locations: Downtown Boston, Suburban Boston (Framingham), Enfield CT www.PerformancePlusBoston.com www.Group-Net.com Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.